List view / Grid view
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
Scientists have made progress in the development of products that improve mitochondrial function...
25 May 2016 | By Victoria White, Digital Content Producer
Thunderbolt is the first company established by Vitesse Biologics, a unique collaboration model formed by Baxalta, Mayo Clinic and VPD...
1 April 2016 | By Victoria White
Astellas and AIST aim to discover new drugs using genome editing technology and a high throughput activity assay for Trypanosoma cruzi...
1 February 2016 | By Victoria White
Astellas and CLINO have entered into a license agreement for the worldwide development and commercialisation of Adeno-associated Virus-modified Volvox channelrhodopsin-1 (AAV-mVChR1)...
14 December 2015 | By Victoria White
Bellicum has been granted rights to develop and commercialise adoptive cell therapies for tumours expressing Prostate Stem Cell Antigen (PSCA) using PCSA technology in-licensed and developed at Agensys...
26 October 2015 | By Victoria White
NVC has already initiated research collaborations with two partners to develop a nosocomial vaccine...
2 June 2015 | By Victoria White
Astellas Pharma and Anokion are to collaborate in the fields of type 1 diabetes and coeliac disease by establishing new drug discovery company Kanyos Bio...
22 April 2015 | By Victoria White
Astellas and Potenza have entered an exclusive R&D collaboration. The agreement includes an option for the future acquisition of Potenza by Astellas...
19 March 2014 | By Daiichi Sankyo
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
